Search fresh public links, source activity, and ready-to-use post angles for Abbv.
Fresh curated links around ABBV are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
A recent analyst lays out a concrete bull case, but it is not the only path to higher prices for AbbVie.
Linked here is a detailed quantitative analysis of Abbott Laboratories (ABT). Below are some highlights from the above linked analysis: Company Description: This diversified healt...
AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.
The healthcare company will release its third-quarter numbers later this month.
AbbVie Oncology Anonymous (not verified) Fri, 10/09/2026 - 07:09 field_thread_url https://cafepharma.com/boards/threads/abbvie-oncology.699564/...
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.
Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.
It would be hard for investors to replicate the company's return over the past decade.
The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.
Another potential blockbuster just joined AbbVie's drug portfolio.
Free cash flow surged over $150M as working capital improved and ERP systems stabilized.
Abbott trades at a 18x forward P/E with $7.4B in free cash flow, while Intuitive Surgical commands a 39x multiple backed by zero debt and 20% revenue growth.
These companies are committed to rewarding shareholders.
The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.
On the NSE, ABD shares were trading at ₹743.55 at the time of the announcement, down 0.68 per cent on the day, against a 52-week high of ₹766.90 hit just four days earlier on Octob...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.